Format

Send to

Choose Destination
Kaohsiung J Med Sci. 2019 Jul 24. doi: 10.1002/kjm2.12104. [Epub ahead of print]

The prognostic value of CSN6 expression in upper tract urothelial carcinomas.

Jhan JH1, Lee YC2,3, Li WM1,2,4,5, Chang LL2,6, Hsu WC2, Lin HH1, Liang PI7, Hsu YL2, Wu WJ1,2,4,8, Lee HY2,4,9, Li CC1,4, Yeh HC1,4, Ke HL1,2,4.

Author information

1
Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
2
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
3
Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
4
Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
5
Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan.
6
Department of Microbiology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
7
Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
8
Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung, Taiwan.
9
Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.

Abstract

CSN6 is a subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN). CSN is involved in cellular and developmental processes such as signal transduction, transcriptional activation, cell cycle control, and tumorigenesis. CSN6 is highly expressed in several human cancers, including colorectal cancer, and breast cancer. However, no previous research has elaborated on the relationship between CSN6 expression and survival in patients with upper tract urothelial carcinoma (UTUC). Therefore, the purpose of this study is to evaluate the clinical significance of CSN6 in UTUC. CSN6 expression in 89 patients with UTUC enrolled in this study was examined using immunohistochemistry. The associations between CSN6 expression and clinicopathological variables were analyzed. CSN6 expression was significantly correlated with patients with high pathological stage (P = .006), male gender (P = .025), and high serum creatinine levels (P = .014). In univariate and multivariable analysis, high CSN6 expression was associated with a higher bladder recurrence (P = .005) and poor cancer-specific survival (P = .001) for UTUC. In conclusion, CSN6 expression is a potential biomarker for predicting cancer recurrence and clinical survival in UTUC. Further research is necessary to investigate its role in the progression of UTUC.

KEYWORDS:

CSN6 (COP9 signalosome subunit 6); bladder recurrence; cancer-specific survival; immunohistochemistry; upper tract urothelial carcinoma

PMID:
31339657
DOI:
10.1002/kjm2.12104
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center